You are here

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

Last updated on June 14, 2018

FOR MORE INFORMATION
Study Location
Oncology Hematology Associates
Springfield, Missouri, 65807 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Non-Small Cell Lung Cancer, Urothelial Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Non-small cell lung cancer (NSCLC) Cohort: Histologically or cytologically confirmed
diagnosis of NSCLC that is locally advanced or metastatic; No activating EGFR
mutations, ALK or ROS1 translocations/rearrangements where testing is standard of
care; received at least 1 prior platinum‑based chemotherapy regimen for locally
advanced or metastatic NSCLC; No more than 2 prior lines of systemic therapy for
locally advanced or metastatic disease (If disease progression occurred during or
within 6 months after neoadjuvant/adjuvant chemotherapy or radiotherapy‑chemotherapy,
the regimen is counted as 1 prior treatment regimen towards the allowed limit of prior
treatment regimens); Checkpoint inhibitor naïve.

- Urothelial Cancer (UC) Cohort: Histologically or cytologically confirmed diagnosis of
transitional cell carcinoma (TCC) of the urothelium (if mixed, more than 50% TCC
component) including bladder, urethra, ureters, or renal pelvis that is locally
advanced or metastatic; No prior systemic treatment for locally advanced or metastatic
disease; Prior neoadjuvant or adjuvant therapy is permitted if disease progression
occurred >12 months after the completion of therapy; Checkpoint inhibitor naïve;
Ineligible for receiving cisplatin‑containing front‑line chemotherapy based at least
one of the following criteria: ECOG performance status (PS) 2; Renal dysfunction
(defined as creatinine‑clearance hearing loss (hearing loss measured by audiometry of 25 decibels at two contiguous
frequencies).

- At least 1 measurable lesion by RECIST v1.1 not previously irradiated.

- Availability of an archival FFPE tumor tissue block from primary diagnosis specimen or
metastatic specimen or 15 unstained slides (10 minimum). If an archived sample is not
available, a fresh tumor biopsy must be performed.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. For UC
patients, ECOG performance 2 is permitted (cisplatin ineligibility criterion)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Prior immunotherapy with an anti?PD?1, anti?PD?L1, anti?PD?L2, anti?CD137, anti?OX?40,
anti?GITR, anti?LAG?3, anti?TIM?3 or anti?CTLA?4 antibody (including ipilimumab).

- Newly diagnosed brain metastases or known symptomatic brain metastases requiring
steroids.

- Radiologically documented evidence of major blood vessel invasion or encasement by
cancer or intratumor cavitation, regardless of tumor histology.

- Active autoimmune disease (that might deteriorate when receiving an immunostimulatory
agent).

- Current use of immunosuppressive medication (except for those listed in protocol).

- Known prior severe hypersensitivity to the investigational products /monoclonal
antibodies.

- Known history of immune?mediated colitis, inflammatory bowel disease, immune?mediated
pneumonitis, pulmonary fibrosis.

- NCI CTCAE Grade 3 hemorrhage within 28 days prior to study enrollment.

NCT03472560
Pfizer
Recruiting
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Renal Cell Cancer
NCT02684006
All Genders
18+
Years
Multiple Sites
Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
NCT02573259
All Genders
18+
Years
Multiple Sites
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
NCT02499120
All Genders
18+
Years
Multiple Sites
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
A Phase 2, Open Label Study To Evaluate Safety And Clinical Activity Of Avelumab (Bavencio (Registered)) In Combination With Axitinib (Inlyta (Registered)) In Patients With Advanced Or Metastatic Previously Treated Non-small Cell Lung Cancer Or Treatment Naïve Cisplatin-ineligible Urothelial Cancer Javelin Medley Vegf
This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum containing therapy, and in treatment naïve patients with advanced or metastatic urothelial cancer, who are ineligible for cisplatin containing chemotherapy for their advanced disease.
Not Provided
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Non-Small Cell Lung Cancer
  • Urothelial Cancer
  • Drug: Avelumab (MSB0010718C)
    IV treatment: Avelumab administered at 800 mg IV every two weeks
    Other Name: Bavencio
  • Drug: Axitinib (AG-013736)
    Oral treatment: Axitinib given 5 mg PO BID
    Other Name: Inlyta
Experimental: Avelumab in combination with axitinib
Avelumab administered at 800 mg IV every two weeks in combination with axitinib, 5 mg PO BID.
Interventions:
  • Drug: Avelumab (MSB0010718C)
  • Drug: Axitinib (AG-013736)
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
80
July 22, 2020
July 22, 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Non-small cell lung cancer (NSCLC) Cohort: Histologically or cytologically confirmed diagnosis of NSCLC that is locally advanced or metastatic; No activating EGFR mutations, ALK or ROS1 translocations/rearrangements where testing is standard of care; received at least 1 prior platinum?based chemotherapy regimen for locally advanced or metastatic NSCLC; No more than 2 prior lines of systemic therapy for locally advanced or metastatic disease (If disease progression occurred during or within 6 months after neoadjuvant/adjuvant chemotherapy or radiotherapy?chemotherapy, the regimen is counted as 1 prior treatment regimen towards the allowed limit of prior treatment regimens); Checkpoint inhibitor naïve.
  • Urothelial Cancer (UC) Cohort: Histologically or cytologically confirmed diagnosis of transitional cell carcinoma (TCC) of the urothelium (if mixed, more than 50% TCC component) including bladder, urethra, ureters, or renal pelvis that is locally advanced or metastatic; No prior systemic treatment for locally advanced or metastatic disease; Prior neoadjuvant or adjuvant therapy is permitted if disease progression occurred >12 months after the completion of therapy; Checkpoint inhibitor naïve; Ineligible for receiving cisplatin?containing front?line chemotherapy based at least one of the following criteria: ECOG performance status (PS) 2; Renal dysfunction (defined as creatinine?clearance <60 ml/min); Grade 2 peripheral neuropathy; Grade 2 hearing loss (hearing loss measured by audiometry of 25 decibels at two contiguous frequencies).
  • At least 1 measurable lesion by RECIST v1.1 not previously irradiated.
  • Availability of an archival FFPE tumor tissue block from primary diagnosis specimen or metastatic specimen or 15 unstained slides (10 minimum). If an archived sample is not available, a fresh tumor biopsy must be performed.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. For UC patients, ECOG performance 2 is permitted (cisplatin ineligibility criterion)

Exclusion Criteria:

  • Prior immunotherapy with an anti?PD?1, anti?PD?L1, anti?PD?L2, anti?CD137, anti?OX?40, anti?GITR, anti?LAG?3, anti?TIM?3 or anti?CTLA?4 antibody (including ipilimumab).
  • Newly diagnosed brain metastases or known symptomatic brain metastases requiring steroids.
  • Radiologically documented evidence of major blood vessel invasion or encasement by cancer or intratumor cavitation, regardless of tumor histology.
  • Active autoimmune disease (that might deteriorate when receiving an immunostimulatory agent).
  • Current use of immunosuppressive medication (except for those listed in protocol).
  • Known prior severe hypersensitivity to the investigational products /monoclonal antibodies.
  • Known history of immune?mediated colitis, inflammatory bowel disease, immune?mediated pneumonitis, pulmonary fibrosis.
  • NCI CTCAE Grade 3 hemorrhage within 28 days prior to study enrollment.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
Not Provided
 
 
NCT03472560
B9991027
2017-004345-24 ( EudraCT Number )
AVE/ AXI COMBO UC ( Other Identifier: Alias Study Number )
AVE/AXI COMBO UC/NSCLC ( Other Identifier: Alias Study Number )
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: Yes
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...
URL: http://
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
March 2018

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now